Literature DB >> 12605770

[Valvular heart disease associated with benfluorex].

Josefa Rafel Ribera1, Roser Casañas Muñoz, Nuria Anguera Ferrando, Nuria Batalla Sahún, Alberto Castro Cels, Ramon Pujadas Capmany.   

Abstract

We report the first case of valvular heart disease due to benfluorex. A 50-year-old woman who had been taking the anorectic agent benfluorex intermittently for one year developed severe fibrosis and regurgitation of the mitral, aortic and tricuspid valves. Clinical, echocardiographic and histopathological findings were analogous to those reported with fenfluramine and dexfenfluramine. The similarity between the histopathological lesion documented in patients treated with the appetite suppressants fenfluramine, dexfenfluramine and benfluorex and the valvular lesions reported in valve disease associated with ergot alkaloid use and carcinoid heart disease suggest a common pathophysiological mechanism and a central role for serotonin in the development of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605770     DOI: 10.1016/s0300-8932(03)76849-3

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  3 in total

1.  Undergraduate and postgraduate pharmacovigilance education: A proposal for appropriate curriculum content.

Authors:  Raquel Herrera Comoglio
Journal:  Br J Clin Pharmacol       Date:  2020-02-05       Impact factor: 4.335

2.  Benfluorex and unexplained valvular heart disease: a case-control study.

Authors:  Irène Frachon; Yves Etienne; Yannick Jobic; Grégoire Le Gal; Marc Humbert; Christophe Leroyer
Journal:  PLoS One       Date:  2010-04-12       Impact factor: 3.240

3.  Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus.

Authors:  Geneviève Derumeaux; Laura Ernande; André Serusclat; Evelyne Servan; Eric Bruckert; Hugues Rousset; Stephen Senn; Luc Van Gaal; Brigitte Picandet; François Gavini; Philippe Moulin
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.